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Apocynin is a naturally occurring methoxy-substituted catechol, experimentally used as an inhibitor of NADPH-oxidase. It can
decrease the production of superoxide (O2
−) from activated neutrophils and macrophages while the ability of phagocytosis
remains unaﬀected. The anti-inﬂammatory activity of apocynin has been demonstrated in a variety of cell and animal models
of inﬂammation. Apocynin, after metabolic conversion, inhibits the assembly of NADPH-oxidase that is responsible for reactive
oxygenspecies(ROS)production.Itis,therefore,extensivelyusedtorevealtheroleofthisenzymeincellandexperimentalmodels.
Although some of the ROS serve as signaling molecules in the cells, excessive production is damaging and has been implicated to
play an important role in the progression of many disease processes. This is why in many studies apocynin presents a promising
potential treatment for some disorders; however, its utility with inﬂammatory diseases remains to be determined. Since its mode
of action is not well deﬁned, we tried to get a more precise insight into the mechanisms by which apocynin exerts its activity.
Considering the anti-inﬂammatory activities of apocynin, we may conclude that this compound deﬁnitely deserves further study.
Copyright © 2008 J. Stefanska and R. Pawliczak. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Oxidative stress describes an imbalance between reactive
oxygen species (ROS) synthesis and antioxidants. The
normal production of oxidants is counteracted by several
antioxidative mechanisms in the body [1, 2].
Normally, cells possess antioxidant defense systems that
include ROS degrading molecules (ROS scavengers), such as
uric acid, ascorbic acid, and sulfhydryl-containing molecules
(e.g., glutathione), and antioxidant enzymes, such as cata-
lase, glutathione peroxidase, and superoxide dismutases. In
pathologic conditions, in which excessive production of ROS
outstrips endogenous antioxidant defense, oxidative stress
may irreversibly modify (oxidize) biologic macromolecules
such as DNA, protein, carbohydrates, and lipids. Enhanced
generation of O2
− also causes loss of NO bioavailability.
O2
− and NO undergo a very fast radical-radical termination
reaction to yield a secondary oxidizing species, peroxynitrite
anion (ONOO
−), and peroxynitrous acid. ROS induce
apoptotic cell death in various cell types, and deregulation
of apoptosis causes clinical disorders [3]. NADPH-oxidase is
the enzyme responsible for ROS production, and inhibition
of this enzyme represents an attractive therapeutic target
for the treatment of many diseases. To counteract oxidative
stress, the body produces an armory of antioxidants to
defend itself, which in fact are sometimes insuﬃcient to
eﬀectively defend the organism from ROS [2, 4]. There are a
lot of substances that have been researched in order to ﬁnd
a way to inhibit production of ROS, and thus protect the
body from diseases. Apocynin, NADPH-oxidase inhibitor, is
one of such agents; however, it is considered variously in
publications. Some of these were found to have potential
clinical success while others have already been abandoned
again, as will be discussed in this short selective review.
2. APOCYNIN
The apocynin (4-hydroxy-3-methoxyacetophenone, trivial
names: apocynin, acetovanillone) was ﬁrst described by
Schmiedeberg in 1883 and was isolated from the roots of
Apocynum cannabinum (Canadian hemp), and extracts of it
were used as oﬃcial remedies for dropsy and heart troubles.
In 1971, apocynin was identiﬁed during activity-guided
isolation of immunomodulatory constituents from the root
of Picrorhiza kurroa (Scrophulariaceae), a native plant grown
in the mountains of India, Nepal, Tibet, and Pakistan, well2 Mediators of Inﬂammation
known in traditional Indian medicine (Ayurveda). Apocynin
is an acetophenone with a molecular weight of 166.17 and
forms needles upon crystallization from water. It possesses a
faint vanilla odor and has a melting point of 115◦C[ 4, 5].
Apocynin has been used as an eﬃcient inhibitor of
the complex NADPH-oxidase in many experimental models
involving phagocytic and nonphagocytic cells [6, 7]. The
mechanism of inhibition is not totally known, but involves
the impairment of the translocation to the membrane of
the cytosolic component p47phox of the NADPH-oxidase
complex [8, 9].
Averyimportantﬁndingconcerningthismechanismwas
the discovery that apocynin is a prodrug that is converted
by peroxidase-mediated oxidation to a dimer, which has
been shown to be more eﬃcient than apocynin itself [10]
(Figure 1).
Apocyninisaninhibitoroftheintracellulartranslocation
of two critical cytosolic components of the NADPH-oxidase
complex present in the cell membrane [9].
The structure of NADPH-oxidase is quite complex, con-
sisting of two membrane-bounded elements (gp91phox and
p22phox), three cytosolic components (p67phox, p47phox
andp40phox), andalow-molecular-weightGprotein(either
rac 2 or rac 1). The racs are kept inactive by binding to a
guaninenucleotidedissociationinhibitor,whichpreventsthe
exchange of guanine nucleotides from the rac proteins [5].
Activation of NADPH-oxidase is associated with, and prob-
ably caused by, the migration of the cytosolic components
to the cell membrane so that the complete oxidase can be
assembled [11].
Apocynin is a selective inhibitor of NADPH-oxidase
activity and concomitant ROS production (IC50 value:
10μM) in activated human neutrophils [12]. Interestingly,
it does not seem to interfere with the PMNs other defense
mechanisms, as it does not aﬀect phagocytosis or intracellu-
lar killing [2].
Apocynin prevents the translocation of p47phox to Nox2
in leukocytes, monocytes, and endothelial cells [2, 10]
(Figure 2). The inhibitory action of the compound, however,
occurs after a lag time only. The latter process appears to
involve MPO because apocynin does not inhibit the oxidase
i nc e l l sd e v o i do rd e ﬁ c i e n to fM P O[ 13], and agents such
as zymosan that promote the release of MPO enhance the
eﬃcacy of apocynin [14].
Intheoriginalreportofapocynin,asanNADPH-oxidase
inhibitor,itwasnotedthatthecompoundrequiresactivation
bymyeloperoxidase(MPO)[12].Itisassumedthatapocynin
is activated by H2O2 and MPO to form an apocynin radical,
which then oxidizes thiols in the NADPH-oxidase. Indeed,
thiols are critical for the function of p47phox, and thiol
oxidizing agents have been shown to block NADPH-oxidase
activation [10, 15]. In line with this concept, it was observed
that supplementation of thiol provided either as glutathione
or cysteine prevents the inhibitory eﬀect of apocynin on the
NAPDH oxidase. An alternative explanation for the lag time
of the inhibitory eﬀect of apocynin was that through the
step of an apocynin radical, an apocynin dimer is formed
[16]. In fact, it has been suggested that this dimer only is the
activeinhibitorycompoundthatmayblockNADPH-oxidase
activity [14].
The in vitro anti-inﬂammatory eﬀects of apocynin
include the following:
(i) the reduction of neutrophil oxidative burst,
(ii) neutrophil-mediated oxidative damage [12],
(iii) the decreased adhesion of the monocytic cell line
U937 to tumor necrosis factor (TNF) treated human
umbilical vein endothelial cells [5],
(iv) a reduction of polymorphonuclear granulocyte
chemotaxis [17],
(v) the inhibition of peroxynitrite [18],
(vi) the inhibition of inﬂammation-mediated cartilage
destruction [6].
Not much is known about the kinetics of apocynin in vivo,
but interesting metabolic aspects of apocynin were described
by Daly et al. [19]. He showed that after a period of 20 hours
upon IP administration of 120mg/kg apocynin to rats, 80%
of the apocynin was recovered unchanged in the urine of the
animals. Side eﬀects of apocynin are not known. Apocynin
has very low toxicity (LD50: 9g/kg) after oral administration
in mice [20].
3. APPLICATION: RESPIRATORY SYSTEM
AND ASTHMA
Ischemia-reperusion lung injury is a well-known clinical
phenomenoncharacterizedbyincreasedpulmonaryvascular
permeability, edema, and resistance to blood ﬂow [21, 22].
The pathogenesis of this injury appears to involve the
generation of ROS, which can be detected during both
ischemia and reperfusion [23, 24]. The ability of superoxide
dismutase to attenuate ischemia-reperfusion lung ininjury
suggests that superoxide anion production represents a
critical step in the process [25, 26]. Apocynin has been
shown to confer protection in animal models of arthritis
[27], and in ozone and endotoxin-induced lung injury
[13, 28]. Doddo et al. [21] showed that apocynin prevents
the increased vascular permeability caused by ischemia and
reperfusion in isolated sheep lungs. The eﬀect of apocynin
on the changes in vascular permeability after ischemia-
reperfusionwasdose-dependent.Thissuggeststhatapocynin
is able to maintain normal endothelial albumin permeability
during ischemia and reperfusion.
P. kurroa, as mentioned previously, has been used for
ages in the treatment of asthma. Peters et al. [9]o b s e r v e d
a statistically signiﬁcant and pronounced eﬀect of apoc-
ynin on ozone-induced bronchial hyperresponsiveness to
methacholine measured 16 hours after exposure to ozone
in mild asthmatics. In addition, apocynin did not prevent
the decline of FEV1 measured directly after ozone exposure,
excluding a possible scavenger eﬀect by apocynin of ozone.
These results suggest that apocynin may have a role in
preventing ozone-induced exacerbations of asthma and
extend the results of Kudo et al. which reported the eﬀect of
apocynin on ozone-induced airway hyperresponsiveness inJ. Stefanska and R. Pawliczak 3
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Figure 1: Creating active form of apocynin-dimerization.
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Figure 2: The mechanism of NADPH-oxidase inhibition by apocynin.
guineapigs[29,30].Thepublicationshowedthatsuperoxide
dismutase, a scavenger of superoxide, as well as apocynin,
reduced O3-induced airway hyperresponsiveness. It was
previously described that peroxidase activation of apocynin
is a prerequisite for inhibition of NADPH-oxidase and that
this activated apocynin is unlikely to work at distances such
as in the airway epithelium [9].
A possible explanation for the eﬀectiveness of apocynin
in the treatment of respiratory diseases might be the fact
that apocynin inhibits peroxynitrite (ONOO
−) formation
[18]. ONOO
− is the very reactive product of the reaction of
nitric oxide (NO) and superoxide anion (•O2
−). For many
years, much attention has been paid to the eﬀects of NO
in respiratory diseases [31], but recently, the focus has been
shifted toward reactive nitrogen species (RNS) in general,
and to peroxynitrite in particular [32, 33]. Peroxynitrite
is suggested to induce epithelial damage, mediator release,
and consequently hyperresponsiveness [34]. This ﬁnding
may have important clinical implications since airway
inﬂammation, epithelial damage, and hyperresponsiveness
are characteristic features in patients suﬀering from asthma.
4. APPLICATION: NEUROPROTECTIVE FEATURES
NADPH-oxidase-mediated superoxide plays an important
role in the pathogenesis of brain injury and that inhibition
of NADPH-oxidase by apocynin can attenuate brain injury
following experimental ischemic stroke [35]. It has been
reported that apocynin protects against global cerebral
ischemia-/reperfusion-induced oxidative stress and injury4 Mediators of Inﬂammation
in the gerbil hippocampus [36], and inhibiting superoxide
production by NADPH-oxidase with apocynin protects
blood-brain barrier constituents in ischemia-like injury in
vitro [37]. Wang et al. investigated that apocynin was able
to protect against brain injury in a collagenase-induced
rat model of intracerebral hemorrhage (ICH). Apocynin
reduced cerebral and vascular injury in experimental stroke
models at doses similar to those used in the present study
[38].
On the other hand, Titova et al. claim that apocynin
should not be considered as a potential therapeutic agent
in ICH, as ICH results in the activation of NADPH-oxidase
and brain injury that cannot be countered by a clinically
relevant administration of apocynin. Additionally, it is
reported that apocynin had no eﬀects not only on enhanced
NADPH-oxidase activity but also on lipid peroxidation and
brain water content, as well as the profound neurological
dysfunction that occurred after ICH [39].
However, the results of Tang’s study suggest that an
increase in NADPH-oxidase activity may contribute to
the enhancement of superoxide in the infarct area, and
NADPH oxidase-mediated superoxide production may play
a crucial role in the pathogenesis of ischemic brain injury.
Apocynin has been shown to confer protection in animal
models of ischemia-/reperfusion-induced lung injury. It
was administrated intraperitoneally, and treatment with
apocynin signiﬁcantly decreased NADPH-oxidase activity
and reduced the superoxide level, in addition to attenuating
signiﬁcantly the size of the infarct [35].
Inﬂammation following ischemic stroke is known to
contribute to injury. Apocynin has been studied as a
potential treatment in experimental stroke. Tang et al. [40]
explored the eﬀect of diﬀerent doses of apocynin in a mouse
model of 2-hour transient middle cerebral artery occlusion
followed by 22-hour reperfusion. Apocynin, given at a
dose of 2.5mg/kg 30 minutes before reperfusion, improved
neurological function, reduced infarct volume, and reduced
theincidenceofcerebralhemorrhage.Nevertheless,athigher
doses of 3.75 and 5mg/kg, it increased brain hemorrhage.
Apocynin also tended to reduce mortality at the lower dose,
but not at higher doses. This data suggest that apocynin
can protect against experimental stroke, but with a narrow
therapeutic window [40].
5. APPLICATION: ARTERIOSCLEROSIS
AND HYPERTENSION
Atherosclerosis is one of the most common cardiovascular
diseases in developed countries and is yet another disease
in which ROS are thought to play an important role [41].
Among the main causes of the development of atherosclero-
sisisahighserumleveloflow-densitycholesterol-containing
lipoprotein [42].
Experiments with apocynin in endothelial cells showed
similar results compared with the eﬀects of apocynin in
phagocytes. Holland et al. reported that endothelial cells,
incubated with apocynin (600μM )a n ds t i m u l a t e dw i t h
the phospholipase A2 activator thrombin, showed NADPH-
oxidase inhibition, resulting in a signiﬁcantly impaired ROS
production[43].Thesameauthorsalsostatethatendothelial
cell incubation with apocynin markedly diminished high
LDL-induced increases in cellular H2O2 concentrations
[44]. Furthermore, apocynin was shown to be eﬀective at
suppressing atherogenesis in vivo in spite of highly elevated
serum low density lipoprotein (LDL) levels using a rabbit
model [45]. So, maybe apocynin has revealed a new strategy
in the treatment of atherosclerosis, and, therefore, future
treatments should also focus on NADPH-oxidase inhibition
as an eﬀective way of preventing the endothelium from the
initiating events of atherosclerosis.
Apocynin is a reversible inhibitor of NAD(P)H oxidase
activity that impedes assembly of the p47phox subunit
with the membrane complex [46]. It has recently been
proposed as a potential therapeutic agent in the treatment of
atherosclerotic disease by Meyer and Schmitt [47]. Increased
levels of reactive oxygen species, in particular O2
−,a r ea
major cause of endothelial dysfunction in many forms of
cardiovascular disease. One of the most important sources
of O2
− is NAD(P)H oxidases [48]. Hamilton et al. [49]h a v e
shown that treatment of isolated rat arteries with apocynin
decreased NADH-stimulated O2
− generation and increased
NO bioavailability. In addition, in human arteries and veins,
NADH- and NADPH-oxidase-mediated O2
− generation was
inhibited by apocynin; endothelium-dependent vasodila-
tion was improved; and NO production from human SV
endothelial cells was enhanced [49].
Nox2 (formerly known as gp91phox) expression is
upregulated and is associated with elevated endothelial and
adventitial NADPH-oxidase-dependent superoxide produc-
tion in model of vascular remodelling, leading to endothelial
nitric oxide dysfunction [50, 51].
Direct inhibition of the source of superoxide gener-
ation with apocynin may well be a useful approach to
reduce the remodelling associated with the early stages of
postangioplasty remodelling or atherosclerosis [47]. Local
administration of an NADPH-oxidase inhibitor apocynin in
vivotothecollaredarteriesattenuatessuperoxideproduction
andpreventsvascularinjuryassociatedwiththisremodelling
[21].
Apocynin treatment of the collared arteries did not
aﬀect Nox2 mRNA expression, thus indicating that apocynin
reduced superoxide generation in the collared arteries by
suppressing the NADPH-oxidase activity rather than aﬀect-
ing its gene transcription. Apocynin has been demonstrated
to reverse endothelial NO dysfunction in animals or humans
subjected to oxidative stress [49]. Several studies have
reported the protective eﬀect of in vivo treatment with apoc-
ynin in experimental vascular injury models associated with
ROS overproduction. Beswick et al. [52]a n dG h o s h e t a l .
[53] showed that extended oral treatment of apocynin
not only reduces superoxide generation in arteries isolated
from deoxycorticosterone acetate salt- (DOCA-) induced
hypertensive rats, but also reduces blood pressure associated
with hypertension [52, 53]. Apocynin inhibits the generation
of NADPH-derived superoxide and prevents the damaging
interactionbetweenNOandsuperoxidetoformmorepotent
ROS, thereby maintaining endothelial function despite the
stimulus for arterial remodelling [54].J. Stefanska and R. Pawliczak 5
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and superoxide-stimulated cell proliferation in the neoin-
tima contributes to intimal hyperplasia in this collar model.
Targeting NADPH-oxidase via adventitial drug delivery
not only reduces superoxide generation, but also nor-
malises endothelial cell function [54]. Targeting the primary
source of NADPH-oxidase-derived superoxide is an eﬀec-
tive approach to prevent deleterious arterial remodelling,
providing a rationale for designing more eﬃcacious and
selective inhibitors of vascular NADPH-oxidase as potential
therapeutics for human vascular disease. Reactive oxygen
species (ROS) are thought to play an important role in
atherogenesis. It has been demonstrated that the Nox2
catalytic component of NADPH-oxidase is upregulated in
a non-hyperlipidemic rabbit model of early stage arterial
remodelling [50, 55].
Apocynin has shown promising application in animal
studies of hypertension and other cardiovascular diseases.
In the Dahl salt-sensitive rat, apocynin inhibits superoxide
production in the renal medulla and decreases hyperten-
sion [56]. DOCA-induced increases in aortic and renal
superoxide production and hypertension are also attenuated
by apocynin treatment [52, 57]. In this model, apocynin
inhibits ﬂow-induced superoxide production in the thick
ascending loop of Henle, which is thought to mediate
inappropriate NaCl retention in salt-sensitive hypertension
[58] and prevents endothelial dysfunction [53]. Apocynin
alsopreventsandreversesincreasesinsystolicbloodpressure
(SBP) in dexamethasone-induced hypertension [59]. Fur-
thermore, apocynin might be eﬀective in treating humoral
forms of hypertension such as those induced by Ang II and
aldosterone.
Apocynin decreased p22phox mRNA levels in aortic
segments from aldosterone-salt male Sprague-Dawley (SD)
rats and impeded p47phox subunit assembly within the
membrane complex in human endothelial cells to inhibit the
activity of NAD(P)H oxidase and its production of super-
oxide. Apocynin prevents and reverses adrenocorticotropic
hormone-(ACTH-)inducedhypertension[2,49],indicating
that NAD(P)H oxidase is a major enzymatic source of
superoxide overproduction in rat model of both naturally
occurring and synthetic hypertension. Apocynin prevented
and reversed Dex-induced changes in SBP, suggesting that
upregulation of superoxide production in Dex-hypertension
is related to increased NAD(P)H oxidase activity [35].
Apocynin may have potential negative eﬀects, causing
a defect in bactericidal phagocytosis which can mimic a
chronic granulomatous disease (CGD) by indirect inhibition
of respiratory burst. Nevertheless, Wilkins et al. [60]c l a i m
that NADPH-oxidase is not required for LDL oxidation
by human monocyte-derived macrophages because human
monocyte-derived macrophages (HMDMs) from chronic
granulomatous disease patients were able to oxidize LDL
as suggested by increased lipoprotein uptake by mouse
macrophages.
Ontheotherhand,Aviram et al.[61]statethatactivation
of NADPH-oxidase is essential for macrophage-mediated
oxidation of LDL. However, HMDM from patients with
CGD that were shown to lack active NADPH-oxidase, but
to possess almost normal 15-1ipoxygenase activity, failed to
oxidize LDL. The study shows that addition of apocynin
to an incubation system completely blocked the release of
superoxides to the medium, suggesting that LDL-induced
macrophage release of superoxides under oxidative stress is
indeed associated with lipoprotein stimulation of cellular
NADPH-oxidase activity.
Although it can be questionable if apocynin may indeed
have potential negative eﬀect triggering a defect in bacterici-
dal phagocytosis which can mimic CGD, reversible character
of action of apocynin and ambiguity of available data display
that this problem still needs investigation.
6. APPLICATION: COX-2 AND CARTILAGE
Hougee et al. [5]c o n ﬁ r m e dt w oi m p o r t a n tf e a t u r e so f
apocynin in vivo: (1) oral administration of apocynin can
partially reverse the inﬂammation-induced inhibition of
cartilage proteoglycan synthesis, and (2) oral administration
of apocynin has COX inhibitory eﬀects similar to the
nonsteroidal anti-inﬂammatory drug (NSAID) ibuprofen.
Therefore, apocynin might be of potential use during
the treatment of chronic inﬂammatory joint diseases like
osteoarthritis or rheumatoid arthritis [5, 16].
Apocynin has been reported to inhibit the superoxide
generating enzyme NADPH-oxidase [12, 13] present in
chondrocytes [62, 63]. Peroxynitrite is the highly reactive
couplingproductofsuperoxideandnitricoxideandhasbeen
suggested to play a role in the inﬂammation-mediated inhi-
bition of cartilage proteoglycan synthesis [43]. By inhibiting
either NO or superoxide production, the amount of concur-
rently generated peroxynitrite would be decreased. More-
over, another recent study showed that apocynin prevented
COX-2 expression in stimulated human monocyte [8]. The
mechanism of action involved the inhibition of the NADPH-
oxidase-dependent superoxide production, the reduction of
the intracellular GSH/GSSG ratio, and the prevention of the
activation of the nuclear transcription factor NF-κB, which
is an important mediator of inﬂammation [5, 64].
However, the recent ﬁnding that apocynin is capable of
preventing COX-2 expression might provide an additional
explanation for the anti-inﬂammatory eﬀects of apocynin
t h a th a v eb e e no b s e r v e di nv i v o .T h e s ei nv i v oe ﬀects of
apocynin include the reduction of arthritis incidence [11],
decreased joint swelling in collagen-induced arthritis in mice
[27, 65], as well as the reduction of ulcerative skin lesions in
inﬂamed skin in rats [66]. Apocynin also prevented airway
hyperresponsiveness during allergic reactions in mice [67]
and reduced airway hyperreactivity to metacholine when
inhaled by humans suﬀering from mild atopic asthma [9].
The COX-2 enzyme and its major metabolite prostaglandin
E2 (PGE2) play an important role during inﬂammatory dis-
eases. For example, in osteoarthritis and rheumatoid arthri-
tis, COX inhibitors such as NSAIDs are used to treat joint
swelling and pain [68–70]. By inhibiting the formation of
superoxide with apocynin, and hence reducing the amount
of peroxynitrite, the inﬂammation-mediated reduction of
proteoglycan synthesis might be restored. In vitro, this has
been demonstrated in human cartilage [5, 6, 11].6 Mediators of Inﬂammation
7. OBJECTS
Aseriouspotentialproblemcomesfromstudiesshowingthat
apocynin may actually increase oxidative stress under some
conditions. Glutathione expression is decreased in response
to apocynin treatment in alveolar epithelial cells [16, 71]
and apocynin activation by myeloperoxidase produces an
apocynin-free radical that is able to oxidize glutathione [16].
Glial cells treated with apocynin show a dose-dependent
increase in oxidative stress markers, including increases
in oxidized glutathione. Unfortunately, apocynin must be
administered at high doses for eﬀectiveness [71].
Apocynin evoked, in a signiﬁcant way, an increase
of H2O2 concentration and a decrease of the intracellu-
lar glutathione/glutathione disulﬁde ratio, accompanied by
augmented eﬄux of glutathione and glutathione disulﬁde.
Apocynin induced the activation of both pentose phosphate
pathway (PPP) and tricarboxylic acid cycle, which was
blocked when the cells were incubated with glutathione
together with apocynin [36, 47, 72]. The cell incubation with
glutathione prevented also the apocynin-induced increase
of malonyldialdehyde generation and lactate dehydrogenase
leakage. Apocynin exerted an oxidant eﬀect also in a cell-
free system: indeed, in aqueous solution, it evoked a faster
oxidation of the thiols glutathione and dithiothreitol, and
elicited the generation of reactive oxygen species, mainly
superoxide anions. This suggests that apocynin per se can
induce an oxidative stress and exert a cytotoxic eﬀect in
diﬀerent cell types, and that some eﬀects of apocynin
in experimental models in vitro and in vivo should be
interpreted with caution [16, 47].
Also, according to Riganti et al. [73] apocynin is able
to increase the H2O2 level in resting monocyte-like cells
(i.e., the N11 glial cell line) and can induce, under longer
times of exposure, an oxidative damage and a cytotoxic
eﬀect. Therefore, it is suggested that apocynin is per se an
inducer of ROS production, independent of the cell type.
It is conceivable that, when NADPH-oxidase is maximally
activated, the inhibition of the respiratory burst is the
prevailing eﬀect of the drug, but in absence of a stimulation
of NADPH-oxidase, the oxidative eﬀect of apocynin itself
could predominate. Additionally, Riganti et al. hypothesize
that since sulfhydryl groups are important for the function
of the leukocyte NADPH-oxidase, the oxidant eﬀect of
apocynin could participate to the mechanism of enzyme
inhibition [71, 73].
Apocynin induces activation of both PPP and tricar-
boxylicacidcycle,whichissubsequenttotheoxidativestress,
because the presence of GSH in the medium together with
apocynin actually blocks the activation of both metabolic
pathways. Riganti et al. [71] hypothesized that apocynin is
able to increase the H2O2 level in resting monocyte-like cells
(i.e., the N11 glial cell line) and can induce under longer
times of exposure an oxidative damage and a cytotoxic eﬀect.
Therefore, it is suggested that apocynin is an inducer of ROS
production, independent of the cell type. It is conceivable
that when NADPH-oxidase is maximally activated, the
inhibition of the respiratory burst is the prevailing eﬀect of
the drug, as a wide body of literature has already shown,
but in absence of a stimulation of NADPH-oxidase, the
oxidative eﬀect of apocynin itself could predominate. It
may be also hypothesized that since sulfhydryl groups are
important for the function of the leukocyte NADPH-oxidase
[13, 16], the oxidant eﬀect of apocynin could participate to
the mechanism of enzyme inhibition. It has been already
reported that apocynin may exert other eﬀects beside its
ability to inhibit NADPH-oxidase: for instance, it inhibits
cytochrome P450 activity in endothelial cells [74], interferes
with actin polymerization and cytoskeletal rearrangement
in polymorphonuclear granulocytes [17], and modulates
the arachidonic acid metabolism through a not-yet-clariﬁed
mechanism [55, 71].
8. SCAVENGER PROPERTIES
According to Heum¨ uller et al. [75], apocynin predominantly
acts as an antioxidant but not as an inhibitor of NADPH-
oxidases in nonphagocytic cells in culture. It failed to
block the O2
− production of Nox1, Nox2, or Nox4 when
overexpressedinendothelialcells.Moreover,invascularcells,
a similar activation of apocynin, as seen in leukocytes, was
not observed. Most importantly, however, apocynin turned
out to be a scavenger of radicals and directly inhibited the
ROS-induced signaling in vascular cells [54, 76].
Titova et al. [39] found that apocynin and its oxidation
products do not react with GSH. However, this thiol
compound was eﬃciently oxidized by the apocynin radical
during the MPO-catalyzed oxidation. The strong inhibitor
eﬀect of apocynin on the production of hypochlorous acid
by stimulated neutrophils might be the result of an additive
eﬀect of NADPH-oxidase inhibition and, to a lesser extent
in less extension, due to competition with chloride for the
catalytic active site of MPO. This is a further evidence of
the importance of apocynin as an anti-inﬂammatory drug
[10]. Titova et al. [39] veriﬁed that neither apocynin nor the
dimer and trimer derivatives were able to conjugate with
GSH,whichisacommonrepresentativeofthiolcompounds.
However, they obtained strong evidence that GSH is able to
react with apocynin radical and/or its dimer radical, which
are formed during MPO-catalyzed oxidation.
Stolk et al. [13] showed that apocynin did not scavenge
superoxide anion generated by xanthine oxidase. They con-
cluded,however,thatapocyninscavengedhydrogenperoxide
because of a dose-response inhibition of luminol-enhanced
chemiluminescence generated by hydrogen peroxide. The
protective eﬀect of apocynin may not be limited to NADPH-
oxidase inhibition. Apocynin has been shown to inhibit
cytochrome P450 [11] and thromboxane synthase [55].
Interestingly, both cytochrome P450 [77] and thrombox-
ane [78] have been implicated as mediators of ischemia-
reperfusion lung injury.
9. APOCYNIN AND CANCER
Klees et al. [79] reported that while apocynin itself is not
eﬀective, its derivatives inhibit migration of the breast
cancer cell line MDAMB-435 at subtoxic concentrations
and the migration of nonmalignant MCF10A breast cellsJ. Stefanska and R. Pawliczak 7
is unaﬀected. These compounds also cause a signiﬁcant
rearrangement of the actin cytoskeleton, cell rounding,
and decreased levels of active Rac1 and its related G
protein Cdc42. The possible link between apocynin and
Rac1 inhibition suggests that apocynin may be a source
for inhibitors of Rac1-mediated tumor cell migration.
Klees et al. reports the application of an in vitro screening
assay to identify apocynin-derived inhibitors of Rac1-based
tumor cell migration. According to this study, apocynin,
upon peroxidase-catalyzed metabolic activation, interferes
with NADPH-oxidase and inhibits lymphocyte migration
through a G-protein-regulated pathway without aﬀecting
adhesion. Reactive oxygen species generated by NADPH-
oxidase also control actin structure [80]. Apocynin or its
metabolites have also been shown to aﬀect the migration of
polymorphonuclear granulocytes, suggesting that its mech-
anism of action is conserved throughout cell types [4, 79].
Active Rac1 is necessary for the translocation of p47-phox
and p67-phox though it does not mediate it directly. Rac1’s
role in NADPH-oxidase activation is not well understood,
but it is able to bind p67-phox, and this binding may be
whatcausestheﬁnalformationoftheactiveNADPH-oxidase
complex. When Rac1 is in its inactive form, there is a
decreased level of O2
−, signifying inactive NADPH-oxidase
[8]. NADPH-oxidase has also been shown to associate with
the actin cytoskeleton, implicating another mode, by which
Rac1 may manage cytoskeletal structure [49, 79].
10. CONCLUSION
Taken together, there is increasing support to consider
using apocynin as a therapeutic agent for treatment of
inﬂammatory diseases. The data of many experiments show
thatNADPH-oxidaseisanimportantcontributortoelevated
levels of ROS. The property of apocynin as an inhibitor
of NADPH-oxidase and its dependence on MPO-catalyzed
oxidation might be linked to the reaction of apocynin radical
and/or its dimer radical with intracellular GSH or directly
with essential thiols of the cytosolic factor p47phox and this
fact might be a key to further experiments, exploring wider
application of apocynin [16, 81, 82].
Summarizing all the applications of apocynin and taking
into account its low toxicity, selectivity, and lack of known
side eﬀects, it can be concluded that apocynin deserves
further attention and that studies to elucidate its mode
of action may contribute to the development of safe and
selective anti-inﬂammatory drugs which lack the often
s e r i o u ss i d ee ﬀects of steroids.
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